What would a Harris or Trump presidency imply for well being care coverage? Why did Eli Lilly’s Mounjaro and Zepbound gross sales miss expectations? And does Adam consider in ghosts?
We speak about all that and extra on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favourite candies — and Eli Lilly and Pfizer’s shock earnings reviews. Then, they talk about what a Trump or Harris presidency might imply for well being care and the biopharma trade, and what buyers and biopharma executives take into consideration both final result.
For extra on Eli Lilly’s shock earnings miss, go right here; to learn how Pfizer beat expectations and responded to activist investor pressures, go right here; for Adam’s column on Trump, RFK Jr. and biotech shares, go right here; to learn how a second Trump administration might change well being care, go right here; and for extra on how a Harris presidency might impression well being care, go right here.
Make sure to enroll in “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.